Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ipilimumab - Bristol-Myers Squibb

Drug Profile

Ipilimumab - Bristol-Myers Squibb

Alternative Names: Anti CTLA-4 monoclonal antibody - Medarex; BMS-734016; MDX-010; MDX-CTLA-4; Yervoy

Latest Information Update: 29 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex
  • Developer Aduro BioTech; AIO Studien gGmbH; Australian and New Zealand Urogenital and Prostate Cancer Group; Bavarian Nordic; Big Ten Cancer Research Consortium; Bristol-Myers Squibb; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; European Thoracic Oncology Platform; Grupo Espanol Multidisciplinar de Melanoma; Icahn School of Medicine at Mount Sinai; Intergroupe Francophone de Cancerologie Thoracique; Ludwig Institute for Cancer Research; Massachusetts General Hospital; Medarex; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Olivia Newton-John Cancer Research Institute; Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University College London; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Renal cell carcinoma
  • Preregistration Colorectal cancer; Non-small cell lung cancer
  • Phase III Gastric cancer; Glioblastoma; Head and neck cancer; Mesothelioma; Oesophageal cancer; Prostate cancer; Small cell lung cancer; Urogenital cancer
  • Phase II Adrenocortical carcinoma; Breast cancer; CNS cancer; Gastrointestinal cancer; Genitourinary disorders; Gynaecological cancer; Liver metastases; Meningeal carcinomatosis; Myelodysplastic syndromes; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Penile cancer; Solid tumours; Thyroid cancer; Uveal melanoma
  • Phase I/II Diffuse large B cell lymphoma; Liver cancer; Lung cancer
  • No development reported HIV infections; Lymphoma

Most Recent Events

  • 28 Nov 2018 No recent reports of development identified for phase-I development in Malignant-melanoma(Inoperable/Unresectable, Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV, Infusion)
  • 15 Nov 2018 The Committee for Medicinal Products for Human Use of EMA adopts a positive opinion recommending approval of nivolumab in combination with ipilimumab for the treatment of Renal cell carcinoma
  • 05 Nov 2018 Bristol-Myers Squibb initiates a phase II trial for Glioblastoma (Combination therapy, Second-line therapy or greater, Recurrent, Late-stage disease) in USA (NCT03430791)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top